Từ khóa
Ban xuất huyết giảm tiểu cầu huyết khối, thiếu máu tán huyết vi mạch, nhồi máu cơ tim, ADAMTS-13.
Tóm tắt
Ban xuất huyết giảm tiểu cầu huyết khối (Thrombotic thrombocytopenia purpura: TTP) là một dạng bệnh hiếm gặp, đặc trưng bởi thiếu máu tán huyết vi mạch (Microangiopathic hemolytic anemia: MAHA), giảm tiểu cầu nặng và
Cụm 'thiếu máu cơ quan đích kết quả do' diễn đạt không chuẩn; nên sửa thành tổn thương/thiếu máu cục bộ cơ quan đích do hình thành vi huyết khối. Cần rà soát ngôn ngữ y khoa toàn bài.
Tài liệu tham khảo
[1]
Sukumar S, Lämmle B, Cataland SRJJocm: Thrombotic thrombocytopenic purpura: pathophysiology, diagnosis, and management. 2021, 10(3):536.
Google Scholar
[2]
Chiasakul T, Cuker A: Clinical and laboratory diagnosis of TTP: an integrated approach. Hematology American Society of Hematology Education Program 2018, 2018(1):530-538.
Google Scholar
[3]
Bendapudi PK, Li A, Hamdan A, Uhl L, Kaufman R, Stowell C, Dzik W, Makar RS: Impact of severe ADAMTS13 deficiency on clinical presentation and outcomes in patients with thrombotic microangiopathies: the experience of the Harvard TMA Research Collaborative. British journal of haematology 2015, 171(5):836-844.
Google Scholar
[4]
Scully M, Rayment R, Clark A, Westwood JP, Cranfield T, Gooding R, Bagot CN, Taylor A, Sankar V, Gale D et al: A British Society for Haematology Guideline: Diagnosis and management of thrombotic thrombocytopenic purpura and thrombotic microangiopathies. British journal of haematology 2023, 203(4):546-563.
Google Scholar
[5]
Balduini CL, Gugliotta L, Luppi M, Laurenti L, Klersy C, Pieresca C, Quintini G, Iuliano F, Re R, Spedini P et al: High versus standard dose methylprednisolone in the acute phase of idiopathic thrombotic thrombocytopenic purpura: a randomized study. Ann Hematol 2010, 89(6):591-596.
Google Scholar
[6]
Scully M, Cohen H, Cavenagh J, Benjamin S, Starke R, Killick S, Mackie I, Machin SJ: Remission in acute refractory and relapsing thrombotic thrombocytopenic purpura following rituximab is associated with a reduction in IgG antibodies to ADAMTS-13. British journal of haematology 2007, 136(3):451-461.
Google Scholar
[7]
Vendramin C, McGuckin S, Alwan F, Westwood JP, Thomas M, Scully M: A single-center prospective study on the safety of plasma exchange procedures using a double-viral-inactivated and prion-reduced solvent/detergent fresh-frozen plasma as the replacement fluid in the treatment of thrombotic microangiopathy. Transfusion 2017, 57(1):131-136.
Google Scholar
[8]
McCulloch R, Bull T, Nicolson PL, Shaw RJ, Sayar Z, Langridge A, Pettitt M, Perry R, Tucker D, Scully MJB: Factors influencing time from initial presentation to start of plasma exchange (PEX) in patients with acute thrombotic thrombocytopenic purpura (TTP). 2020, 136:9-10.
Google Scholar
[9]
Hawkins BM, Abu-Fadel M, Vesely SK, George JN: Clinical cardiac involvement in thrombotic thrombocytopenic purpura: a systematic review. Transfusion 2008, 48(2):382-392.
Google Scholar
[10]
Gandhi K, Aronow WS, Desai H, Amin H, Sharma M, Lai HM, Singh P: Cardiovascular manifestations in patients with thrombotic thrombocytopenic purpura: a single-center experience. Clinical cardiology 2010, 33(4):213-216.
Google Scholar
[11]
Hosler GA, Cusumano AM, Hutchins GM: Thrombotic thrombocytopenic purpura and hemolytic uremic syndrome are distinct pathologic entities. A review of 56 autopsy cases. Archives of pathology & laboratory medicine 2003, 127(7):834-839.
Google Scholar
[12]
Benhamou Y, Boelle PY, Baudin B, Ederhy S, Gras J, Galicier L, Azoulay E, Provôt F, Maury E, Pène F et al: Cardiac troponin-I on diagnosis predicts early death and refractoriness in acquired thrombotic thrombocytopenic purpura. Experience of the French Thrombotic Microangiopathies Reference Center. Journal of thrombosis and haemostasis : JTH 2015, 13(2):293-302.
Google Scholar
[13]
Page EE, Kremer Hovinga JA, Terrell DR, Vesely SK, George JN: Rituximab reduces risk for relapse in patients with thrombotic thrombocytopenic purpura. Blood 2016, 127(24):3092-3094.
Google Scholar